|Venture Round, 8/07 |
Stanford Financial Group
KineMed is a leader in Translational Medicine (TM) and Personalized Medicine (PM).
TM & PM are two keys to unlocking future growth in the pharmaceutical sector. After several spectacular decades of astonishing R&D productivity associated with impressive value creation, pharmaceutical companies are fighting for their futures. This reflects many challenges, amongst which one of the biggest and most crucial is flagging R&D productivity. TM & PM have the potential to revitalize the pharmaceutical sector by driving R&D productivity. Leveraging ground-breaking science from the laboratories of Professor Marc Hellerstein, M.D., Ph.D., KineMed has invested a decade and over $60 MM to create state-of-the-art capabilities in Translational and Personalized Medicine applicable across many therapy areas.